NCT01334879View on ClinicalTrials.gov

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Radiation Retinopathy
Interventions
DRUG

ranibizumab 2.0 mg

Intravitreal ranibizumab (2.0 mg)

Trial Locations (1)

10065

The New York Eye Cancer Center, New York

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

The New York Eye Cancer Center

OTHER

NCT01334879 - High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy | Biotech Hunter | Biotech Hunter